LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Accueil・Liste d'Actions・Design Therapeutics Inc

Design Therapeutics Inc

Fermé

10.6 -0.84

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.47

Max

10.87

Chiffres clés
By Trading Economics
Revenu	-1.6M -18M
BPA	-0.29
Employés	54
EBITDA	-1.5M -20M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+82.16% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-148M 652M
Ouverture précédente	11.44
Clôture précédente	10.6

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juin 2026, 19:20 UTC

Principaux Mouvements du Marché

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 juin 2026, 21:27 UTC

Résultats

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 juin 2026, 20:19 UTC

Acquisitions, Fusions, Rachats

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 juin 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 juin 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 juin 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 juin 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 juin 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 juin 2026, 18:33 UTC

Acquisitions, Fusions, Rachats

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 juin 2026, 17:50 UTC

Résultats

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 juin 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 juin 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 15:44 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 juin 2026, 15:25 UTC

Résultats

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 juin 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 juin 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 juin 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 juin 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

82.16% hausse

Prévisions sur 12 Mois

Moyen 19.6 USD 82.16%

Haut 22 USD

Bas 15 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.